A Contact Tracing Trial Comparing the Diagnostic Performance of C-Tb to QuantiFERON®-TB, in Combination With a Safety Assessment of C-Tb Versus Tuberculin PPD RT23 SSI

Condition(s): Tuberculosis
NCTId: NCT01631266

Official Title

A Phase III Contact Tracing Trial Comparing the Diagnostic Performance of C-Tb to QuantiFERON®-TB Gold In-Tube, in Combination With a Double Blind Randomized Split Body Safety Assessment of C-Tb Versus 2 T.U. Tuberculin PPD RT23 SSI

Summary

Tuberculosis (TB) continues to be the most important bacterial infection worldwide and therefore new improved diagnostic tests are needed to help doctors in diagnosing TB.

We are investigating a new skin test named C-Tb. Like the current tuberculin skin test (PPD), the C-Tb test is injected just under the skin and will, when positive, show redness and/or swelling at the injection site while a negative test will leave no reactions.

The aim of this trial is to test the C-Tb skin test in volunteers. The volunteers are divided into four groups:

- Negative control group: Must have no history of exposure to a person with tuberculosis disease.

- Occasional contact: Must be in contact with a person with tuberculosis disease between 6 hours/week and 6 hours/day

- Close contact: Must be in close contact with a person with tuberculosis disease for more than 6 hours/day for at least five days

- Positive control group: Must have a confirmed tuberculosis disease within the last 3 years.

The goals of this clinical trial are:

- To compare the C-Tb test to a blood test, the QuantiFERON test.

- To compare the C-Tb test to the PPD test that is currently being used.

- To assess the safety of the C-Tb test.

Detailed Description

The TESEC-06 trial is an open comparison of the diagnostics performance of C-Tb compared to QuantiFERON®-TB Gold In-Tube, in combination with a double-blind randomized split-body safety assessment of C-Tb versus Tuberculin PPD RT23 SSI.

The trial is designed to address the fundamental issue that in the diagnosis of latent tuberculosis (TB) infection, no gold standard exists. Thus, no existing test for latent TB is 100 % sensitive and specific - including the Tuberculin PPD RT23 SSI and QuantiFERON®-TB Gold In-Tube.

This will be addressed by evaluating C-Tb positive response rates in 4 groups defined by their estimated risk of infection with MTb. The groups will consist of paediatric and adult participants selected as being either occasional or close contacts to an active pulmonary TB case. In addition a group of confirmed TB cases and a group of participants with no history of exposure to MTb will be included as control groups.

50 participants in the negative control group will be tested with C-Tb alone in order to evaluate whether concomitant administration of C-Tb and Tuberculin PPD RT23 SSI could conceivably result in larger or smaller areas of induration to one or both tests as a result of expanding the clone of sensitised T-cells i.e. since Tuberculin PPD RT23 SSI includes among several other antigens ESAT-6 and CFP-10 and C-Tb also contains both these antigens.

Eligibility

Eligibility Criteria

Gender Minimum Age Maximum Age Healthy Volunteers?
Both 6 Weeks 65 Years True

Inclusion Criteria:

1. Can comply with one of the following groups:

1. Negative control group: Must have no history of exposure to a TB index case, and have no signs or symptoms of TB

2. Positive control group: Confirmed TB disease within the last 3 years by sputum smear microscopy and/or Culture, Gene Xpert or PCR

3. Close contact group: Must be in close contact with a pulmonary smear positive TB index case for more than 6 hours/day for at least five days

4. Occasional contact group: Must be in contact with a pulmonary sputum smear positive TB index case between 6 hours/week and 6 hours/day

2. Is between 6 weeks - 65 years of age

3. Participant, parent or legal guardian has provided signed informed consent

4. Is willing and likely to comply with the trial procedures

5. Is prepared to grant authorized persons access to their medical records

Exclusion Criteria:

1. Has been vaccinated with a live vaccine within 6 weeks prior to the day of inclusion (e.g. Mumps Measles Rubella (MMR), yellow fever, oral typhoid vaccines)

2. Has been tuberculin tested less than 12 months prior to the day of inclusion

3. Is pregnant, breastfeeding or intending to get pregnant within the trial period

4. Is a female of child bearing potential (12 years of age or older having had their first menstruation) not willing to use effective barrier (including spermicidal gel), hormonal or intrauterine contraceptive measures within the trial period

5. Has an active disease affecting the lymphoid organs except for HIV (e.g., Hodgkin's disease, lymphoma, leukaemia, sarcoidosis)

6. Has a current skin condition which interferes with the reading of the C-Tb and Tuberculin PPD RT23 SSI e.g. tattoos, severe scarring, burns/sunburns, rash, eczema, psoriasis, or any other skin disease at or near the injection sites

7. Has a condition where blood drawings pose more than minimal risk for the participant, such as haemophilia, other coagulation disorders, or significantly impaired venous access

8. Current participation in another clinical trial with an investigational or non investigational drug or device, which in the opinion of investigator may interfere with this trial drug

9. Has participated in previous clinical trials investigating injections with ESAT-6 and/or CFP-10 antigens

10. Has a condition which in the opinion of the investigator is not suitable for participation in the trial

Interventions & Outcomes

Study Interventions & Types

Biological Intervention(s)

2 T.U. Tuberculin PPD RT 23 SSI - The 2 T.U. Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
C-Tb - The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme

Study Outcomes

Primary Outcome(s)

Timeframe: Onset between the injections and 28 days after the injections
Measure: To demonstrate an increasing trend in C-Tb test positivity across the four study groups, with 'positivity' defined as an induration ≥ 5 mm
Safety Issue? No

Secondary Outcome(s)

Measure: To compare the diagnostic outcome of C-Tb and PPD RT23 SSI stratified on the four study groups
Timeframe: Onset between the injections and 28 days after the injections
Safety Issue? No

Measure: To compare the diagnostic outcome of C-Tb and QuantiFERON Gold In-Tube stratified on the four study groups
Timeframe: From the day of injections to 2-3 days after the injections
Safety Issue? No

Measure: To compare the diagnostic outcome of C-Tb to that of PPD RT23 SSI using a latent class approach
Timeframe: Onset between the injections and 28 days after the injections
Safety Issue? No

Measure: To compare the diagnostic outcome of C-Tb to that of QuantiFERON Gold In-Tube using a latent class approach
Timeframe: From the day of injections to 2-3 days after the injections
Safety Issue? No

Measure: To compare the size of induration of C-Tb if injected alone or concomitantly with PPD RT23 SSI in negative control group
Timeframe: Onset between the injections and 28 days after the injections
Safety Issue? No

Measure: To compare the specificity of C-Tb if injected alone or concomitantly with PPD RT23 SSI, in the negative control group
Timeframe: Onset between the injections and 28 days after the injections
Safety Issue? No

Measure: To demonstrate a significantly lower response rate of C-Tb as compared to that of PPD RT23 SSI in the BCG vaccinated participants in the negative control group, with response defined as any induration (> 1mm) for both agents
Timeframe: Onset between the injections and 28 days after the injections
Safety Issue? No

Measure: To evaluate a possible trend in C-Tb induration diameters across the four pre-specified MTb infection risk sub-groups
Timeframe: Onset between the injections and 28 days after the injections
Safety Issue? No

Measure: To evaluate a possible trend in PPD RT23 SSI induration diameters across the four pre-specified MTb infection risk sub-groups
Timeframe: Onset between the injections and 28 days after the injections
Safety Issue? No

Measure: To evaluate a possible trend in PPD RT23 SSI test positivity across four pre-specified MTb infection risk sub-groups
Timeframe: Onset between the injections and 28 days after the injections
Safety Issue? No

Measure: To evaluate a possible trend in QuantiFERON Gold In-Tube results across four pre-specified MTb infection risk sub-groups
Timeframe: On the day of the injections
Safety Issue? No

Measure: To evaluate a possible trend in QuantiFERON Gold In-Tube test positivity across four pre-specified MTb infection risk sub-groups
Timeframe: On the day of the injections
Safety Issue? No

Measure: To evaluate the clinical safety of C-Tb
Timeframe: Onset between the injections and 28 days after the injections
Safety Issue? Yes

Measure: To evaluate the clinical safety of PPD RT23 SSI
Timeframe: Onset between the injections and 28 days after the injections
Safety Issue? Yes

Measure: To evaluate the difference in sensitivity between C-Tb and PPD RT23 SSI in positive control group
Timeframe: Onset between the injections and 28 days after the injections
Safety Issue? No

Measure: To evaluate the difference in sensitivity between C-Tb and QuantiFERON Gold In-Tube in the positive control group
Timeframe: From the day of injections to 2-3 days after the injections
Safety Issue? No

Measure: To evaluate the difference in specificity between C-Tb and PPD RT23 SSI in the negative control group
Timeframe: Onset between the injections and 28 days after the injections
Safety Issue? No

Measure: To evaluate the difference in specificity between C-Tb and QuantiFERON Gold In-Tube in the negative control group
Timeframe: From the day of injections to 2-3 days after the injections
Safety Issue? No

Measure: To evaluate the secondary analyses above (1-14) of C-Tb and PPD RT23 SSI using alternative cut-off values
Timeframe: Onset between the injections and 28 days after the injections
Safety Issue? No

Facility Locations

Research Study Facility Map

Map of facility locations for this research study.

Facility is recruiting
Facility is not yet recruiting
Unknown status

Clinical Research Study Facility Locations

Complexo Hospitalario Universitario de Vigo
Vigo, Galicia +34 981 950 036 Spain

Complejo Hospitalario Universitario de Santiago
Santiago de Compostela, Galicia 15706 Spain

Complexo Hospitalario de Pontevedra
Pontevedra, Galicia 36071 Spain

Hospital Universitario Lucus Augusti
Lugo, Galicia 27004 Spain

Public Health Agency of Barcelona
Barcelona, Catalonia 08023 Spain

Hospital Vall d'Hebron
Barcelona, Catalonia 08035 Spain

Hospital San Joan De Deu
Barcelona, Catalonia 08950 Spain

Hospital Mutua de Terrassa
Barcelona, Catalonia 08221 Spain

Hospital del Mar
Barcelona, Catalonia 08003 Spain

Hospital de la Santa Creu i Sant Pau
Barcelona, Catalonia 08025 Spain

Hospital Clínic i Provincial de Barcelona
Barcelona, Catalonia 08036 Spain

CAP Drassanes, Unitat de Prevenció i Control de Tuberculosi
Barcelona, Catalonia 08001 Spain

Hospital Universitario de Cruces
Barakaldo, Basque Country 48903 Spain

Related Keywords & Studies

Conditions and Diseases with Related Research Studies

  1. Tuberculosis

Related Tuberculosis Research

  1. A BCG Challenge Model Study to Assess Anti-mycobacterial Immunity Induced by BCG and a Candidate TB Vaccine, MVA85A
  2. A Bioequivalence Study of Two Different Dosages of Isoniazid Tablet Formulations in Human Healthy Volunteers
  3. A Clinical Challenge Study of BCG in Healthy Volunteers
  4. A Controlled Trial of a 4-Month Quinolone-Containing Regimen for the Treatment of Pulmonary Tuberculosis
  5. A Knowledge Translation Intervention for TB/HIV Treatment Adherence, in Zomba District, Malawi
  6. A Phase I Randomized Placebo-Controlled, Double-Blind Study to Evaluate Safety and Immunogenicity of AERAS‑404 Administered as Different Amounts of Antigen and Adjuvant Combinations in HIV-Negative BCG-Vaccinated Adults Without Evidence of Tuberculosis Infection
  7. A Phase I Study of a New Tuberculosis (TB) Vaccine, MVA85A, in Healthy Volunteers With HIV
  8. A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG
  9. A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Received BCG Immunisation 1 Month Previously
  10. A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers.